La lecture en ligne est gratuite
Le téléchargement nécessite un accès à la bibliothèque YouScribe
Tout savoir sur nos offres
Télécharger Lire

Eaton Apothecary Selects Predictive Acquisition Cost (PAC) Drug Price Type

2 pages
Eaton Apothecary Selects Predictive Acquisition Cost (PAC) Drug Price Type PR Newswire TAMPA, Florida, June 28, 2012 TAMPA, Florida, June 28, 2012 /PRNewswire/ -- Holliston, Mass.-based pharmacy chain selects PAC from Elsevier / Gold Standard and Glass Box Analytics Leading drug information provider, Elsevier / Gold Standard, announced today that Holliston, Mass.-based pharmacy chain Eaton Apothecary has purchased the new Predictive Acquisition Cost (PAC), developed by Glass Box Analytics and exclusively sold by Elsevier / Gold Standard. Introduced earlier this year, PAC is a new drug price type that more closely tracks true acquisition cost. PAC employs predictive analytics techniques to estimate acquisition cost considering various factors, including MAC benchmarks, published price lists, existing price benchmarks, drug dispensing metrics, supply-demand measures, and survey-based acquisition costs. Independent tests show that PAC tracks drug acquisition cost with sufficient accuracy to support pricing activity. "Glass Box Analytics has done an exceptional job developing the new price type, PAC," said Eaton Apothecary Vice President of Operating Policy John H. Lynch, III. "We are eager to begin using PAC for our company and look forward to the growth potential the new tool will offer as we integrate its intelligence into our existing systems." Eaton Apothecary has 16 locations, including traditional retail pharmacies and those focused on home delivery and specialized care.
Voir plus Voir moins
Eaton Apothecary Selects Predictive
Acquisition Cost (PAC) Drug Price Type
PR Newswire
TAMPA, Florida, June 28, 2012
TAMPA, Florida
,
June 28, 2012
/PRNewswire/ --
Holliston, Mass.-based pharmacy chain selects PAC from Elsevier / Gold
Standard and Glass Box Analytics
Leading drug information provider, Elsevier / Gold Standard, announced today
that
Holliston, Mass.
-based pharmacy chain Eaton Apothecary has purchased
the new Predictive Acquisition Cost (PAC), developed by Glass Box Analytics and
exclusively sold by Elsevier / Gold Standard.
Introduced earlier this year, PAC is a new drug price type that more closely
tracks true acquisition cost. PAC employs predictive analytics techniques to
estimate acquisition cost considering various factors, including MAC
benchmarks, published price lists, existing price benchmarks, drug dispensing
metrics, supply-demand measures, and survey-based acquisition costs.
Independent tests show that PAC tracks drug acquisition cost with sufficient
accuracy to support pricing activity.
"Glass Box Analytics has done an exceptional job developing the new price type,
PAC," said Eaton Apothecary Vice President of Operating Policy John H. Lynch,
III. "We are eager to begin using PAC for our company and look forward to the
growth potential the new tool will offer as we integrate its intelligence into our
existing systems."
Eaton Apothecary has 16 locations, including traditional retail pharmacies and
those focused on home delivery and specialized care. As a classic community-
centered pharmacy, Eaton Apothecary prides itself for its commendable one-
on-one service with patients. With a reputation in the industry as an early-
adopter of new, enhanced technologies and marketplace trends, Eaton
Apothecary selected PAC, adding to the company's competitive edge.
"We are excited to be working with Eaton Apothecary as they begin to
implement PAC into their systems," said Marianne Messer, Elsevier / Gold
Standard President. "We have confidence that PAC meets the industry need for
a drug price type that is a close indicator of true acquisition cost, and is
accurate, transparent, comprehensive and timely."
Eaton Apothecary plans to utilize PAC for reimbursement analysis, wholesaler
request for proposal processes with standards for deviations from the PAC
price type, and as a cash pricing base.
Elsevier / Gold Standard
Based in
Tampa, FL
, Elsevier / Gold Standard uses innovative technologies to
provide a complete suite of drug information and decision support solutions.
With a tenacious commitment to product quality, Elsevier / Gold Standard
solutions empower healthcare organizations, professionals and consumers to
meet the most pressing healthcare challenges, improve patient safety and
ensure optimal outcomes. To learn more about Elsevier / Gold Standard, visit
http://www.goldstandard.com.
About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical
information products and services. The company works in partnership with the
global science and health communities to publish more than 2,000 journals,
including
The Lancet
and
Cell
, and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier's online solutions include
ScienceDirect, Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which
enhance the productivity of science and health professionals, and the SciVal
suite and MEDai's Pinpoint Review, which help research and health care
institutions deliver better outcomes more cost-effectively.
A global business headquartered in
Amsterdam
, Elsevier employs 7,000 people
worldwide. The company is part of Reed Elsevier Group PLC, a world-leading
publisher and information provider, which is jointly owned by Reed Elsevier PLC
and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL
(London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media contact
Tom Reller
Vice President, Global Corporate Relations, Elsevier
+1-215-239-3508
t.reller@Elsevier.com